Leila Farahmand

2.5k total citations · 1 hit paper
74 papers, 1.7k citations indexed

About

Leila Farahmand is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Leila Farahmand has authored 74 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Molecular Biology, 31 papers in Oncology and 20 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Leila Farahmand's work include Monoclonal and Polyclonal Antibodies Research (18 papers), Cancer Cells and Metastasis (13 papers) and Glycosylation and Glycoproteins Research (11 papers). Leila Farahmand is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (18 papers), Cancer Cells and Metastasis (13 papers) and Glycosylation and Glycoproteins Research (11 papers). Leila Farahmand collaborates with scholars based in Iran, United States and Canada. Leila Farahmand's co-authors include Keivan Majidzadeh‐A, Shima Moradi‐Kalbolandi, Behrad Darvishi, Khadijeh Barzaman, Mohammad Hossein Kazemi, Elahe Safari, Jafar Karami, Zeinab Zarei‐Behjani, Mohammad Zarei and Zahra Eslami‐S and has published in prestigious journals such as Nature Communications, Free Radical Biology and Medicine and British Journal of Cancer.

In The Last Decade

Leila Farahmand

73 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Breast cancer: Biology, biomarkers, and treatments

2020 566 citations Khadijeh Barzaman, Shima Moradi‐Kalbolandi et al. International Immunopharmacology profile →

Peers

Leila Farahmand

ONCOL

IMMUN

Mayank Singh India

Cai Yuan China

Min Luo China

Norihiro Kokudo Japan

Letizia Porcelli Italy

Naoyo Nishida Japan

Sonia Molina‐Pinelo Spain

Darran P. O’Connor Ireland

Huanrong Lan China

Guifang Yang China

Mayank Singh India

Leila Farahmand

1.4k ×1.7

682 ×1.2

ONCOL

595 ×1.5

265 ×1.1

IMMUN

221 ×1.0

Citations per year, relative to Leila Farahmand Leila Farahmand (= 1×) peers Mayank Singh

Countries citing papers authored by Leila Farahmand

Since Specialization

Citations

This map shows the geographic impact of Leila Farahmand's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leila Farahmand with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leila Farahmand more than expected).

Fields of papers citing papers by Leila Farahmand

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leila Farahmand. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leila Farahmand. The network helps show where Leila Farahmand may publish in the future.

Co-authorship network of co-authors of Leila Farahmand

This figure shows the co-authorship network connecting the top 25 collaborators of Leila Farahmand. A scholar is included among the top collaborators of Leila Farahmand based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leila Farahmand. Leila Farahmand is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bahraminasab, Marjan, Leila Farahmand, Behrad Darvishi, et al.. (2024). A thermosensitive hydrogel for the sustained delivery of exosomes extracted from menstrual blood mesenchymal stem cells and frizzled antibody on triple-negative breast cancer cells in vitro. Journal of Drug Delivery Science and Technology. 101. 106144–106144. 1 indexed citations

Khaki, Zohreh, et al.. (2023). Development of a MET-targeted single-chain antibody fragment as an anti-oncogene targeted therapy for breast cancer. Investigational New Drugs. 41(2). 226–239. 3 indexed citations

Barough, Mahdieh Shokrollahi, et al.. (2023). Anti–MUC1 nanobody can synergize the Tamoxifen and Herceptin effects on breast cancer cells by inducing ER, PR and HER2 overexpression. International Immunopharmacology. 124(Pt A). 110792–110792. 6 indexed citations

Farahmand, Leila, et al.. (2022). MUC1 is a potential target to overcome trastuzumab resistance in breast cancer therapy. Cancer Cell International. 22(1). 110–110. 23 indexed citations

Majidzadeh‐A, Keivan, et al.. (2022). A Review of the Molecular Mechanisms of EGFR and IGFR Receptors in Tamoxifen Resistance in Breast Cancer. 6(4). 6–16. 2 indexed citations

Yaghmaei, Parichehreh, et al.. (2022). Effects of 1Hz 100mT electromagnetic field on apoptosis induction and Bax/Bcl-2 expression ratio in breast cancer cells. 6(1). 1–7. 1 indexed citations

Majidzadeh‐A, Keivan, et al.. (2021). A comprehensive reference for BRCA1/2 genes pathogenic variants in Iran: published, unpublished and novel. Familial Cancer. 21(2). 137–142. 1 indexed citations

Javidi, Mohammad Amin, Behrad Darvishi, Seyed Peyman Shariatpanahi, et al.. (2021). Necroptosis triggered by ROS accumulation and Ca2+ overload, partly explains the inflammatory responses and anti-cancer effects associated with 1Hz, 100 mT ELF-MF in vivo. Free Radical Biology and Medicine. 169. 84–98. 35 indexed citations

Barzaman, Khadijeh, Shima Moradi‐Kalbolandi, Keivan Majidzadeh‐A, et al.. (2021). Development of a recombinant anti-VEGFR2-EPCAM bispecific antibody to improve antiangiogenic efficiency. Experimental Cell Research. 405(2). 112685–112685. 11 indexed citations

10.

Majidzadeh‐A, Keivan, et al.. (2021). Engineered hypoxia-responding Escherichia coli carrying cardiac peptide genes, suppresses tumor growth, angiogenesis and metastasis in vivo. Journal of Biological Engineering. 15(1). 20–20. 13 indexed citations

11.

Moradi‐Kalbolandi, Shima, Fariba Dashtestani, Keivan Majidzadeh‐A, et al.. (2019). Development of an anti-CD45RA-quantum dots conjugated scFv to detect leukemic cancer stem cells. Molecular Biology Reports. 47(1). 225–234. 5 indexed citations

12.

Farahmand, Leila, et al.. (2018). Stemness Phenotype in Tamoxifen Resistant Breast Cancer Cells May be Induced by Interactions Between Receptor Tyrosine Kinases and ERα-66. Recent Patents on Anti-Cancer Drug Discovery. 13(3). 302–307. 6 indexed citations

13.

Esmaeili, Rezvan, Nasrin Abdoli, Mohamadreza Neishaboury, et al.. (2018). Unique CD44 intronic SNP is associated with tumor grade in breast cancer: a case control study and in silico analysis. Cancer Cell International. 18(1). 28–28. 5 indexed citations

14.

Farahmand, Leila, et al.. (2017). Significant Role of MUC1 in Development of Resistance to Currently Existing Anti-cancer Therapeutic Agents. Current Cancer Drug Targets. 18(8). 737–748. 32 indexed citations

15.

Darvishi, Behrad, Leila Farahmand, Zahra Eslami‐S, & Keivan Majidzadeh‐A. (2017). NF-κB as the main node of resistance to receptor tyrosine kinase inhibitors in triple-negative breast cancer. Tumor Biology. 39(6). 3726132291–3726132291. 33 indexed citations

16.

Farahmand, Leila, et al.. (2017). ER-α36 Interactions With Cytosolic Molecular Network in Acquired Tamoxifen Resistance. Clinical Breast Cancer. 17(6). 403–407. 10 indexed citations

17.

Majidzadeh‐A, Keivan, et al.. (2017). Extremely low frequency magnetic field enhances glucose oxidase expression in Pichia pastoris GS115. Enzyme and Microbial Technology. 98. 67–75. 15 indexed citations

18.

Darvishi, Behrad, Leila Farahmand, & Keivan Majidzadeh‐A. (2017). Stimuli-Responsive Mesoporous Silica NPs as Non-viral Dual siRNA/Chemotherapy Carriers for Triple Negative Breast Cancer. Molecular Therapy — Nucleic Acids. 7. 164–180. 44 indexed citations

19.

Esmaeili, Rezvan, et al.. (2015). AKAP3 correlates with triple negative status and disease free survival in breast cancer. BMC Cancer. 15(1). 681–681. 8 indexed citations

20.

Farahmand, Leila, et al.. (2014). Ligation Independent Cloning of Polycistronic, Genetically Modified, HuMAb4D5-8 F (ab`)2, in Bacterial Plasmid. Europe PMC (PubMed Central). 7(2). 7–15. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact